top of page

A human approach to addiction recovery,
enabled by technology

We provide digital solutions for therapy, rehabilitation and aftercare for addiction.

coobi supports patients with addiction

Our
Mission

Our mission is to make addiction treatment more accessible and efficient through the use of technology. To do this, we are developing an innovative AI-based algorithm that uses digital data from smartphones and wearables to calculate an individual's risk of relapse and provide objective insights into addictive behaviour. This allows us to identify critical periods of abstinence at an early stage. We can then intervene when the user needs it most. These critical-phase interventions are called Just-in-Time Adaptive Interventions (JITAIs) and are based on the latest research. Our aim is to optimize support for people suffering from addiction, their families and caregivers in coping with addiction and reducing relapse.

We offer solutions for...

Our technology is based on the recognition of individual patterns of behaviour and the early detection of critical periods of abstinence. It can therefore be applied to all addictive disorders. We are developing different products for different forms of addiction, as we want to offer tailored solutions in terms of the interventions and user interface of our products.

Our first prototype, coobi cope, uses our technology to reduce problematic and excessive media use. You can read more about our coobi cope prototype here.

We are currently working on solutions that are focused on the clinical use and aftercare of substance-related addictions, such as alcohol addiction. First studies are already planned. More information for therapists and doctors can be found here.

 

Products for other areas are planned.

Media addiction

Internet & Gaming

Alkoholabhängigkeit

Alcohol

Cannabis addiction

Cannabis

Drug absue

Drug abuse

How it works

Datenerhebung mit Garmin Wearables

Data
collection

coobi continuously collects data via a wearable and a smartphone. By measuring the data over a longer period of time, we are able to identify important information and trends that can help the user to understand and change behaviour.

Who coobi can support

Affected individuals

coobi offers tailor-made support to people with addictive disorders, which is adapted to their individual situation and enables them to gain a deeper understanding of their current situation. By providing an insight into the triggers and influences of one's own behaviour and by encouraging reflection, coobi empowers people to make informed choices for their own personal wellbeing.
 

Suchterkrankter
Betroffene, Familie, Partner Suchtererkrankung

Loved ones

Relatives gain insight into their family member/ friend/ partner's condition and can use this as a basis for dealing with the situation better. They will also be informed about the critical moments in which their support will be particularly important in order to accompany their loved one on the road to recovery.

Therapists & Clinics

Clinics and therapists gain access to objective data about the physiological and psychological situation of their patients. This not only saves time, but also provides deeper insights that are not apparent in standard consultations. As a result, the likelihood of long-term improvement increases, as does the success rate of their treatments. 

Therapeut für Abhängigkeitserkrankung

Partners & Sponsors

coobi is part of the Vision Health Pioneers Incubator programme and is funded by the European Social Fund and the Berlin Senate. Furthermore, as a member of the Fraunhofer Ahead Deeptech programme, coobi collaborates with two Fraunhofer Institutions, the IKS and the IAO.

Vision Health Pioneers
Berlin Senat
ESF Berlin
Europäischer Sozialfond
Invest forderungsfähig
AHEAD - Fraunhofer's Deeptech Accelerator
Spinlab.png

White Papers

The concept of coobi is based on scientific principles and the most recent results of research. Find out more in our white papers.

Digital biomarkers have the potential to revolutionise healthcare. What digital biomarkers are, where their potential and limitations lie, and what the future holds is the subject of this white paper.

bottom of page